Journal
LIFE SCIENCES
Volume 294, Issue -, Pages -Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.lfs.2022.120368
Keywords
Melatonin; SARS-CoV-2; COVID-19; Innate immunity; Adaptive immunity; Inflammation; Main protease; Nirmatrelvir; Ritonavir
Ask authors/readers for more resources
Melatonin, a potential drug for treating SARS-CoV-2 infection, can reduce inflammation and mortality by regulating the host immune response. Clinical trials have shown that adding melatonin to conventional therapy significantly reduces the mortality of severe COVID-19 patients. Melatonin has a low cost and high safety margin, making it an affordable treatment option for countries worldwide.
The fear of SARS-CoV-2 infection is due to its high mortality related to seasonal flu. To date, few medicines have been developed to significantly reduce the mortality of the severe COVID-19 patients, especially those requiring tracheal intubation. The severity and mortality of SARS-CoV-2 infection not only depend on the viral virulence, but are primarily determined by the cytokine storm and the destructive inflammation driven by the host immune reaction. Thus, to target the host immune response might be a better strategy to combat this pandemic. Melatonin is a molecule with multiple activities on a virus infection. These include that it downregulates the overreaction of innate immune response to suppress inflammation, promotes the adaptive immune reaction to enhance antibody formation, inhibits the entrance of the virus into the cell as well as limits its replication. These render it a potentially excellent candidate for treatment of the severe COVID-19 cases. Several clinical trials have confirmed that melatonin when added to the conventional therapy significantly reduces the mortality of the severe COVID-19 patients. The cost of melatonin is a small fraction of those medications approved by FDA for emergency use to treat COVID-19. Because of its self-administered, low cost and high safety margin, melatonin could be made available to every country in the world at an affordable cost. We recommend melatonin be used to treat severe COVID-19 patients with the intent of reducing mortality. If successful, it would make the SARS-CoV2 pandemic less fearful and help to return life back to normalcy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available